IL-2 Promising in Treating Moderate to Severe UC
At the Crohn’s and Colitis Congress, an 8-week study was presented showing promising results in using low doses of IL-2 in treating moderate to severe UC. IL-2 or, aldesleukin, is a drug commonly used for melanoma (skin cancer) and RCC, a type of cancer that starts in the kidneys. The medicine works by targeting specific … Read more